Management

Prior to joining TME Pharma in May 2010 as Chief Business Officer, Aram served as Vice-President Business Development for Novexel where he concluded a €150 million licensing agreement including a €75 million upfront payment with Forest Laboratories (NYSE:FRX) for North American rights to a beta-lactamase inhibitor now known as avibactam. Aram was a member of the management team that negotiated the subsequent acquisition of Novexel by AstraZeneca (NYSE:AZN) for up to $505 million.

Aram began his career at ExonHit Therapeutics (now Eurobio Scientific, Euronext:ALERS), where he served in a variety of roles eventually heading the business development function as Vice-President. He concluded a number of important agreements for ExonHit, in particular the $30 million strategic alliance with Allergan. Aram has served as a non-executive member of the boards of two Scandinavian biotechs, Isofol Medical AB, based in Sweden, and C10 Pharma, based in Norway.

Aram received a B.S. from the University of Wisconsin-Madison in biochemistry, molecular biology and English literature, a PhD in Biology from the University of California-San Diego for research carried out at the Salk Institute and an MBA from INSEAD.

Jarl Ulf was CEO of Isofol Medical AB. He also serves on boards of Biovica International, CarpoNovum, Oncopeptides and Ryvu Therapeutics. Jarl Ulf held important responsibilities in the clinical development of several successful oncology drugs, including Abraxane^®, Gemzar^®, Alimta^® and Revlimid^®. He worked at Celgene from 2007 to 2014 where he served as Vice President of Clinical Research and Development, Solid Tumors. Prior to that post Jarl Ulf held leadership positions at Takeda, Pfizer, Eli Lilly & Company and VAXIMM, where he was responsible for clinical development of oncology programs as well as being involved in business development.

He received both a Bachelor of Science degree and his MD from the Karolinska Institute in Stockholm Sweden.

Heike has been involved in raising more than €190 million in financing transactions via diverse financing vehicles. Prior to TME Pharma, Heike held several positions at medium sized companies in the service sector, where she led reorganization and turnaround projects and was in charge of implementing business know-how in technology driven entities. She also lectures business administration and controlling at the University of Potsdam. Heike holds a Doctor in Economics from the University of Leipzig.

Dirk successfully brought three drugs from discovery to the clinic. He led TME Pharma’s collaborations and partnerships with scientific institutions and big pharma such as Merck, Eli Lilly, Pfizer and Roche. Dirk holds a Doctor in molecular biology from the University of Stuttgart and an MBA from the University of Potsdam.

Karen guided the company’s listing on the Euronext Growth in 2016 and negotiated collaboration and licensing agreements with Merck, Pfizer, Roche and Eli Lilly and academic and research organizations both in Europe and the US. Karen has been involved in raising more than €190 million via diverse vehicles since 2001. Karen studied law at the Freie Universität Berlin and joined TME Pharma after her bar exam.

Ewelina brings to TME Pharma over 10 years’ experience in multi-stakeholder international projects and program management in healthcare and business settings. Prior to TME Pharma, she worked at HIMSS, a global health-tech association, and McKinsey & Company. Ewelina holds an MA in Political Strategy and Communication from the University of Kent.